GLP-1R and GCGR in the Treatment of Alcohol-Associated Liver Disorders in Subjects with Obesity or Overweight Human Beings
AssigneeSpitfire Pharma LLC
InventorsBertrand Victor Gilbert Georges, M. Scot Roberts, Sarah K. Browne, Matthew Scott Harris, John Joseph Suschak, III
Life of this patent
Estimating the term…
Abstract
This disclosure relates to the once weekly dosing regimen of a dual GLP-1R and GCGR agonist, formulations, and methods of using the same for treatment of Alcohol Associated Liver Disease (ALD) using a pharmaceutical dosage formulation comprising a peptide product according to SEQ ID NO: 1, or peptide product that is at least 80% identical to a peptide of SEQ ID NO: 1.
Claims24
A method for treatment of Alcohol Associated Liver Disease (ALD) in a human being in need thereof comprising administering to the human being a once weekly therapeutic effective amount of a pharmaceutical dosage formulation comprising a peptide product according to SEQ ID NO:
- 1, or a peptide product that is at least 80% identical to a peptide of SEQ ID NO:
- 1.
(canceled)
16-22. (canceled)
25-27. (canceled)
A method for reducing liver fibrosis in treatment of Alcohol Associated Liver Disease (ALD) in a human being in need thereof comprising administering to the human being a once weekly therapeutic effective amount of a pharmaceutical dosage formulation comprising a peptide product according to SEQ ID NO:
- 1, or peptide product that is at least 80% identical to a peptide of SEQ ID NO:
- 1.
32-57. (canceled)
Dependencies are inferred from the claim text.